Dynavax Technologies Corp - Company Profile

Powered by

All the data and insights you need on Dynavax Technologies Corp in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Dynavax Technologies Corp Strategy Report

  • Understand Dynavax Technologies Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Dynavax Technologies Corp: Overview

Select Item

Related keylists

Dynavax Technologies Corp (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Heplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. It’s pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-ZOS-01 for immune-mediated, herpes zoster, and anaphylaxis events; DV2-HBV-27 for the pregnancy registry. Dynavax also has a vaccine candidate, DV2-TDAP-01 adjuvant, for pertussis. The company operates through its subsidiaries in Germany and India. Dynavax is headquartered in Emeryville, California, the US.

 Gain a 360-degree view of Dynavax Technologies Corp and make more informed decisions for your business Gain a 360-degree view of Dynavax Technologies Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 2100 Powell Street, Suite 720, Emeryville, California, 94608
Website www.dynavax.com
Telephone 1 510 8485100
No of Employees 408
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange DVAX (NASD)
Revenue (2022) $232.3M -67.9% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -102.2% (2022 vs 2021)
Market Cap* $1.5B
Net Profit Margin (2022) XYZ -106.8% (2022 vs 2021)
* As of and is in US$
View Dynavax Technologies Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Dynavax Technologies Corp premium industry data and analytics

50+

Clinical Trials

Determine Dynavax Technologies Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Dynavax Technologies Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Dynavax Technologies Corp’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of Dynavax Technologies Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

15+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Dynavax Technologies Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Dynavax Technologies Corp’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Dynavax Technologies Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Marketed -
Heplisav-B - an Adult Vaccine for Hepatitis B
Pipeline -
XYZ
XYZ
XYZ
Understand Dynavax Technologies Corp portfolio and identify potential areas for collaboration Understand Dynavax Technologies Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In February, the company received approval from Great Britain Marketing Authorization for HEPLISAV B.
2021 Regulatory Approval In December, the company announced that, the vacciene developed by Biological E for Covid using its CpG 1018 Adjuvant recieved India DCGI approval for emergency use.
2021 Contracts/Agreements In October, the company and the U.S. Department of Defense entered into an agreement to develop a recombinant plague vaccine adjuvanted with CpG 1018.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Dynavax Technologies Corp Johnson & Johnson Merck & Co Inc Pfizer Inc Sanofi
Headquarters United States of America United States of America United States of America United States of America France
City Emeryville New Brunswick Kenilworth New York Paris
State/Province California New Jersey New Jersey New York Ile-de-France
No. of Employees 408 131,900 72,000 88,000 87,994
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Scott Myers Director; Chairman Executive Board 2021 56
Ryan Spencer Chief Executive Officer Senior Management 2019 45
Kelly MacDonald Chief Financial Officer Senior Management 2021 39
David F. Novack President; Chief Operating Officer Senior Management 2019 61
Robert Janssen, M.D. Senior Vice President - Clinical Developement; Chief Medical Officer Senior Management 2013 69
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Dynavax Technologies Corp key executives to enhance your sales strategy Gain insight into Dynavax Technologies Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward